Heartburn: Pathophysiology, Risk Factors, Diagnosis, and Evidence-Based Management in Adults and Older Patients

Heartburn refers to the retrosternal burning sensation commonly associated with gastroesophageal reflux disease (GERD). Although many people use the term interchangeably with “acid reflux,” clinically heartburn is a symptom, not a diagnosis. It typically arises when gastric contents—especially acid and pepsin—reflux into the esophagus and irritate the esophageal mucosa. The core mechanism involves transient relaxation of the lower esophageal sphincter (LES), which normally functions as a barrier to backflow. Additional contributors include increased intra-abdominal pressure, delayed gastric emptying, hiatal hernia, and impaired esophageal clearance due to reduced peristaltic activity. When reflux episodes occur repeatedly, esophageal epithelial injury and neurogenic hypersensitivity can develop, producing persistent or escalating symptoms even when measured acid exposure is not dramatically elevated.

Risk factors for heartburn and GERD are multifactorial. Common behavioral and physiological contributors include overweight and obesity (through higher abdominal pressure), dietary triggers such as high-fat meals, chocolate, peppermint, and alcohol, and timing factors like lying down soon after eating. Smoking is associated with impaired LES function and altered mucosal defense. Medications that can relax the LES or impair motility—such as certain calcium channel blockers, anticholinergics, nitrates, and some antidepressants—may worsen symptoms. Pregnancy increases reflux prevalence via hormonal effects and mechanical pressure. People with dyspepsia, impaired esophageal motility, or hiatal hernia are also at higher risk. Importantly, there is a distinction between typical heartburn and other causes of chest discomfort, which is clinically relevant because cardiac etiologies must be excluded when alarm features are present.

Diagnosis is primarily clinical for uncomplicated cases: if a patient reports classic heartburn occurring with reflux-related patterns and no red flags, initial empiric therapy is often appropriate. Red flags include dysphagia, odynophagia, gastrointestinal bleeding (hematemesis or melena), unexplained weight loss, anemia, persistent vomiting, or progressive symptoms. In such cases, endoscopy is recommended to evaluate for erosive esophagitis, peptic stricture, Barrett’s esophagus, or malignancy. For patients with persistent symptoms despite optimized treatment, ambulatory reflux monitoring can be used to correlate symptoms with acid exposure and to distinguish acid reflux from non-acid reflux. Esophageal manometry may be considered when surgery is contemplated or when motility disorders are suspected, because abnormal peristalsis and LES function influence treatment choice.

Management begins with lifestyle and behavioral interventions. Weight reduction is strongly supported for overweight individuals. Patients are advised to avoid meals close to bedtime and consider elevating the head of the bed. Dietary modifications are individualized, though empiric elimination of known personal triggers may help. Smaller meals and slower eating can reduce reflux burden. For some patients, reducing alcohol and smoking cessation improve outcomes. Pharmacologic therapy is stepwise and evidence-based: antacids provide rapid, short-duration relief by neutralizing gastric acid; alginate-based products form a physical barrier that can reduce postprandial reflux. H2-receptor antagonists (e.g., famotidine) decrease acid secretion and are useful for mild or intermittent symptoms. Proton pump inhibitors (PPIs) are the most effective class for frequent heartburn, especially when erosive disease is present; they suppress gastric acid secretion by inhibiting the H+/K+ ATPase. Clinically, PPIs should be taken 30–60 minutes before breakfast for maximal efficacy, because their mechanism depends on activating proton pumps during meals.

For patients with incomplete response, clinicians reassess adherence, timing, and dosing, and consider escalating therapy, adding bedtime H2 blockers for nocturnal symptoms, or using adjunctive strategies such as alginates. Long-term PPI therapy requires periodic reassessment to balance symptom control against potential risks. While observational studies suggest associations with nutrient deficiencies (e.g., magnesium, vitamin B12), increased fracture risk, chronic kidney disease signals, and certain infections, the absolute risks are generally low and must be contextualized. The safest approach is the lowest effective dose with periodic attempts to step down if symptoms are controlled.

Heartburn can also relate to conditions such as eosinophilic esophagitis, non-erosive reflux disease, functional heartburn, or reflux hypersensitivity. Functional heartburn is characterized by typical symptoms without objective reflux evidence, often involving altered pain perception and heightened visceral sensitivity. In these cases, the treatment strategy may incorporate neuromodulators and targeted behavioral therapy rather than solely escalating antisecretory drugs.

When severe or refractory disease persists, procedural options may be considered. Antireflux surgery (e.g., fundoplication) or endoscopic therapies are generally reserved for carefully selected patients with confirmed reflux and appropriate anatomy. Prior to such interventions, objective testing helps identify true reflux-driven disease and ensures that esophageal motility is adequate.

Overall, heartburn is a symptom with a mechanistic spectrum involving LES dysfunction, reflux burden, esophageal clearance impairment, and hypersensitivity. Effective care integrates alarm screening, appropriate diagnostic testing when needed, lifestyle modification, and stepwise medication using PPIs as first-line therapy for frequent symptoms. Source: HarriedFord8647 (X post)